Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The company is headquartered in South San Francisco, California and currently employs 250 full-time employees. The company went IPO on 2024-06-28. The firm is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Follow-Up Questions
Alumis Inc의 CEO는 누구입니까?
Mr. Martin Babler은 2021부터 회사에 합류한 Alumis Inc의 Chairman of the Board입니다.
ALMS 주식의 가격 성능은 어떻습니까?
ALMS의 현재 가격은 $4.2이며, 전 거래일에 decreased 6.43% 하였습니다.
Alumis Inc의 주요 사업 주제나 업종은 무엇입니까?
Alumis Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Alumis Inc의 시가총액은 얼마입니까?
Alumis Inc의 현재 시가총액은 $437.1M입니다
Alumis Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 9명의 분석가가 Alumis Inc에 대한 분석 평가를 실시했으며, 이는 6명의 강력한 매수, 7명의 매수, 1명의 보유, 0명의 매도, 그리고 6명의 강력한 매도를 포함합니다
